|
USA-3641-Electric Lamp Bulbs and Tubes Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- Home | Aquestive Therapeutics
Aquestive Therapeutics is the undisputed leader in developing and delivering medications via film, through our proprietary PharmFilm® technology We’ve used our expertise to create a robust, proprietary, and complex molecule portfolio Learn about the medicines we’re reinventing to improve treatment options for patients
- Aquestive Therapeutics Announces FDA Acceptance of New Drug Application . . .
About Aquestive Therapeutics Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care
- FDA accepts NDA for epinephrine sublingual film to treat type 1 . . .
The FDA has accepted a new drug application (NDA) for epinephrine sublingual film (Anaphylm; Aquestive Therapeutics) to treat type 1 allergic reactions, including anaphylaxis With the acceptance of the application, the federal agency has assigned a target action date of January 31, 2026, for a decision according to a press release from
- Aquestive Therapeutics, Inc. (AQST) - Yahoo Finance
Find the latest Aquestive Therapeutics, Inc (AQST) stock quote, history, news and other vital information to help you with your stock trading and investing
- About Us | Aquestive Therapeutics
Aquestive Therapeutics, Inc (NASDAQ: AQST) is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies
- FDA accepts Aquestive’s NDA for oral epinephrine film with 2026 target . . .
In other recent news, Aquestive Therapeutics reported a challenging first quarter of 2025, with earnings per share of -$0 24, missing the forecast of -$0 16, and revenue of $8 7 million, falling
- Press Releases - Aquestive Therapeutics
WARREN, N J , Feb 20, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it
- Aquestive Therapeutics: Not For Me, But Attractive
Aquestive Therapeutics leverages its PharmFilm technology to develop innovative oral drug delivery systems Find out why I'm neutral on AQST stock
- BRIEF—FDA accepts NDA for Aquestive’s Anaphylm
Aquestive Therapeutics today announced that the US Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Anaphylm sublingual epinephrine film under development as a treatment of Type 1 allergic reactions, including anaphylaxis, for review
- Aquestive Therapeutics Announces FDA Acceptance of New Drug . . . - Nasdaq
About Aquestive Therapeutics Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies We
|
|